The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,733.50
Bid: 1,732.50
Ask: 1,733.00
Change: 0.00 (0.00%)
Spread: 0.50 (0.029%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,733.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 Sinks As Ex-Dividend Shares Drag

Thu, 13th Aug 2020 12:22

(Alliance News) - The London equities market was struggling to find its groove at midday on Thursday, as ex-dividend shares weighed on the FTSE 100 index, while investors await US jobless claims figures this afternoon and agreement on a stimulus package for the world's largest economy.

In London, the blue-chip FTSE 100 index was down 58.79 points, or 0.9%, at 6,221.33. The mid-cap FTSE 250 index was down 59.32 points, or 0.3% at 18,030.72. The AIM All-Share index was up 0.2% at 956.60.

The Cboe UK 100 index was down 1.2% at 619.69. The Cboe 250 was flat at 15,435.68, and the Cboe Small Companies was up 0.9% at 9,525.65.

In mainland Europe, the CAC 40 index in Paris was down 0.2%, while the DAX 30 in Frankfurt was down 0.1%.

"A combination of some big stocks trading without the rights to their dividend and a bit of profit-taking after a strong run for equities so far in August saw the FTSE 100 on the back foot on Thursday morning. The index was still north of the 6,200 mark as investors awaited the latest unemployment figures from the US later," said AJ Bell's Russ Mould.

In the FTSE 100, Just Eat Takeaway.com was up 1.3%, adding to a 3.7% rise on Wednesday after a well-received set of interim results.

At the other end of the FTSE 100, a handful of shares traded ex-dividend. Phoenix Group was down 4.1%, Legal & General 2.5%, Aviva also 2.5%, GlaxoSmithKline 2.4%, Royal Dutch Shell 'A' shares down 2.5% and Shell 'B' down 2.4%.

In the mid-cap FTSE 250, Watches of Switzerland was up 19% after the luxury timepiece retailer said it delivered a strong performance in its maiden year as a public company.

The company reported revenue was up 6% to GBP819.3 million for the financial year ended April 26, from GBP797.7 million in financial 2019, and adjusted pretax profit was GBP49.4 million, up 86% from GBP26.5 million.

Going into financial 2021, Watches of Switzerland said it remained positive expecting revenue in a range between GBP840 million to GBP860 million, on the basis of a continued strong luxury watch market in the UK and US.

Revenue expectations also come as the firm slowly grows sale revenue as stores re-open, up 7.4% in July versus a year ago, climbing on a 83% drop in May.

National Express was down 12% as the bus and train operator swung to a bruising loss during its first-half. The company recorded pretax loss swung to GBP122.2 million in the six months to June 30 from a GBP88.4 million profit a year earlier. While revenue dropped 23% to GBP1.03 billion from GBP1.34 billion.

There was no interim dividend, as previously guided, following a 5.16p payout a year ago. There is also no annual profit guidance, due to Covid-19 uncertainty.

Dignity shares were up 42%. The funeral services provider said the industry would "benefit" from having a regulator after the UK competition watchdog found that fees for funerals and cremations have surged in excess of inflation over the past 10 years.

The Competition & Markets Authority back in March of last year set out to investigate concerns it had over the funeral sector. The probe found that because of the "inherent emotional distress", people are less likely to compare prices among funeral providers.

"The CMA has provisionally decided that, in the short term, it will require all funeral directors and crematoria to provide customers with information on, and the prices of, the various services and packages they offer. This will go a long way to ensuring people have easily accessible information on services and costs to help them decide which type of funeral arrangement they require," the regulator said.

New York was pointed for a lower open, as Democrats and Republicans continued to point the finger as to why a US stimulus package cannot be agreed.

The Dow Jones Industrial Average, the S&P 500 index and the Nasdaq Composite were seen down 0.1%, based on futures trading.

Investors are hopeful that Congress will eventually agree on a new pandemic deal despite long-running animosity between Democrats and Republicans.

However, both sides are blaming each other for the lack of progress, with Treasury Secretary Steven Mnuchin saying House Leader Nancy Pelosi would not budge unless the Democrats' demand for spending of at least USD2 trillion is met.

That is well down from the USD3.5 trillion initially proposed by Democrats but Republicans say they are unwilling to shift from their USD1 trillion plan.

The pound was quoted at USD1.3101 Thursday at midday, up from USD1.3044 Wednesday's equities close in London.

The euro was priced at USD1.1844, up from USD1.1794. Against the yen, the dollar was quoted at JPY106.81, soft from JPY106.94 in London.

"In FX the dollar was weaker across the board losing against both euro and cable. With little progress on the negotiations in Washington DC, the bulls may be running out of excuses to take risk assets higher while the buck may be seeing a mild outflow of capital offer as investors remain uncertain about the US economic future," explained analysts at BK Asset Management.

Brent oil was trading at USD45.34 a barrel Thursday midday, firm from USD45.26 a barrel Wednesday evening. Gold was quoted at USD1,930.52 an ounce, lower from USD1,948.50 an ounce at the close Wednesday.

By Arvind Bhunjun, arvindbhunjun@alliancenews.com; and Neetika Kurup, neetikakurup@alliancenews.com

Copyright 2020 Alliance News Limited. All Rights Reserved.

More News
17 Dec 2023 15:16

PRESS: GSK looks for deals in China as rebuilds relationship

(Alliance News) - The Financial Times on Sunday reported that GSK PLC is looking for some new deals in China.

Read more
15 Dec 2023 17:08

European shares end fifth week higher on rate-cut optimism

Barclays sees first ECB rate cut in April

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:22

TOP NEWS: Japan accepts GSK's filing for respiratory disease vaccine

(Alliance News) - GSK PLC on Tuesday said Japan's Ministry of Health, Labour & Welfare has accepted its regulatory application for the extension of its respiratory syncytial virus vaccine, Arexvy, for adults aged 50-59.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:24

GSK seeks to extend RSV vaccine approval in Japan

(Sharecast News) - GSK announced on Tuesday that Japan's Ministry of Health, Labour and Welfare (MHLW) has accepted its regulatory application for the extension of the indication of its RSV vaccine to include adults aged 50- to 59 at an increased risk of contracting the disease.

Read more
11 Dec 2023 08:28

GSK drug gets EU marketing backing for form of endometrial cancer

(Alliance News) - GSK PLC on Monday said it won EU backing for its Jemperli drug in tandem with chemotherapy to treat a form of endometrial cancer.

Read more
11 Dec 2023 07:41

LONDON BRIEFING: GSK drug gets EU endorsement; Begbies backs outlook

(Alliance News) - London's FTSE 100 is called to open a touch lower on Monday, kicking off the week with some slight trepidation after Friday's hotter-than-expected US jobs report which offered the dollar some respite.

Read more
11 Dec 2023 07:23

GSK endometrial cancer treatment gets Europe authorisation

(Sharecast News) - GSK announced on Monday that the European Commission has granted marketing authorisation for 'Jemperli', or dostarlimab, in combination with chemotherapy for certain endometrial cancers.

Read more
7 Dec 2023 12:54

THG backer Kelso pushes for demerger to trim "inherent" valuation gap

(Alliance News) - THG PLC investor Kelso Group Holdings PLC on Thursday reiterated its call for a demerger, which the shareholder believes will help close the "disparity" between the e-commerce firm's share price and its true value.

Read more
5 Dec 2023 10:02

LONDON BROKER RATINGS: Goldman lifts Landsec and British Land

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
27 Nov 2023 09:00

GSK announces positive results from Blenrep phase 3 blood cancer trial

(Alliance News) - GSK PLC on Monday said a phase 3 trial of belantamab mafodotin as a multiple myeloma treatment has produced positive headline results.

Read more
27 Nov 2023 08:02

GSK receives 'positive' headline results from phase III trial

(Sharecast News) - Drugmaker GSK announced on Monday that it had received positive headline results from a planned interim efficacy analysis from a phase III trial evaluating its elantamab mafodotin asset.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.